» Articles » PMID: 7911420

Somatostatin and the Immune and Haematopoetic System; a Review

Overview
Publisher Wiley
Specialty General Medicine
Date 1994 Feb 1
PMID 7911420
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

SS-R and SS have been demonstrated in non-pathological and pathological lymphoid tissue and may play a regulatory, mostly inhibitory, role in the immune response. SS is produced by lymphocytes and monocytes which suggests an autocrine or paracrine regulatory role, but SS may be released as well by nerve endings. It can therefore be hypothesized that apart from a role of SS in local, immunomodulation of cells belonging to the immune system, a second pathway exists in which this peptide exerts its effects via neuroendocrine modulation of the immune response which might represent a direct regulatory relation between the nervous and the immune system. The presence of SS-R in lymphoid neoplasm cells and in diseases involving activated mononuclear leukocytes allows the visualization of these diseases using octreotide scintigraphy. This technique may be used in the evaluation of the spread of these diseases and to monitor their response to therapy. Moreover, the presence of SS-R in immune diseases warrants studies on the efficacy of treatment with octreotide of patients suffering from these diseases.

Citing Articles

Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Alaklabi S, Maguire O, Pattnaik H, Zhang Y, Chow J, Wang J Cancers (Basel). 2024; 16(17).

PMID: 39272962 PMC: 11394651. DOI: 10.3390/cancers16173104.


Structural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists.

Li J, You C, Li Y, Li C, Fan W, Chen Z Proc Natl Acad Sci U S A. 2024; 121(26):e2321710121.

PMID: 38885377 PMC: 11214081. DOI: 10.1073/pnas.2321710121.


Impact of different models based on blood samples and images for bone marrow dosimetry after Lu-labeled somatostatin-receptor therapy.

Vallot D, Brillouet S, Pondard S, Vija L, Texier J, Dierickx L EJNMMI Phys. 2024; 11(1):32.

PMID: 38564043 PMC: 10987460. DOI: 10.1186/s40658-024-00615-5.


EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Sjogreen Gleisner K, Chouin N, Minguez Gabina P, Cicone F, Gnesin S, Stokke C Eur J Nucl Med Mol Imaging. 2022; 49(6):1778-1809.

PMID: 35284969 PMC: 9015994. DOI: 10.1007/s00259-022-05727-7.


Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.

Wang A, Yuan Y, Chu H, Gao Y, Jin Z, Jia Q Pathol Oncol Res. 2022; 28:1610196.

PMID: 35264912 PMC: 8898825. DOI: 10.3389/pore.2022.1610196.